
浏览全部资源
扫码关注微信
纸质出版日期:2012
移动端阅览
石紫云, 王亚琴. 不同方案乙肝免疫球蛋白阻断血清乙肝病毒表面抗原、乙肝病毒阳性孕妇宫内传播的研究[J]. 中国实验方剂学杂志, 2012,18(7):255-257.
SHI Zi-yun, WANG Ya-qin. Contrast Study on Effect of Hepatitis B Immunity Globulin with Different Injection Methods to Interrupt Intrauterine Transmission from Mothers with Positive HBsAg and HBV-DNA Serum to Infants[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(7): 255-257.
石紫云, 王亚琴. 不同方案乙肝免疫球蛋白阻断血清乙肝病毒表面抗原、乙肝病毒阳性孕妇宫内传播的研究[J]. 中国实验方剂学杂志, 2012,18(7):255-257. DOI:
SHI Zi-yun, WANG Ya-qin. Contrast Study on Effect of Hepatitis B Immunity Globulin with Different Injection Methods to Interrupt Intrauterine Transmission from Mothers with Positive HBsAg and HBV-DNA Serum to Infants[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(7): 255-257. DOI:
目的: 探讨采用不同方案孕期使用乙肝免疫球蛋白(HBIG)阻断乙肝病毒宫内传播的效果
以便选择有效且经济的阻断方案。 方法: 选择血清乙肝病毒表面抗原(HBsAg)
乙肝病毒(HBV-DNA)阳性孕妇132例
随机分为A组27例于孕20
24
28
32
36
38周分别肌肉注射HBIG 200 U;B组38例于孕28
32
36周分别肌肉注射HBIG 400 U;C组45例于孕28
32
36周分别肌肉注射HBIG 200 U;对照组22例孕期不进行干预。所有132例新生儿进行HBIG和HBVac的联合免疫。观察7月龄时
婴儿的血清HBV-M和HBV-DNA
比较各组宫内感染率。 结果: A组2例发生宫内感染
宫内感染率7.4%;B组3例发生宫内感染
宫内感染率7.9%;C组5例发生宫内感染
宫内感染率11.1%。对照组8例发生宫内感染
宫内感染率36.4%。A
B
C 3组宫内感染率分别与对照组比较
差异有统计学意义(P<0.05);3组间两两比较
差异无统计学意义。 结论: 孕期使用HBIG阻断HBV宫内感染安全有效
在血清HBsAg
HBV-DNA阳性孕妇群中
选择孕晚期每月注射200 IU可达到与同等剂量分6次注射和高剂量分3次注射相同的效果。从而推断
低剂量分3次注射有效且最经济。
Objective: To study the effect of Hepatitis B immunityglobulin(HBIG) with different injection methods to interrupt inner-uterus transmission from mothers with positive epatitis B surface antigen(HBsAg) and Hepatitis B Virus-DNA(HBV-DNA) serum to infants for the selection of the most effective and cheapest project. Method: One hundred and thirty-two pregnant women with positive HBsAg and HBV-DNA serum were randomly divided into four groups. 200 U HBIG was intramuscularly injected to 27 women of group A at 20
24
28
32
36
38 gestational weeks. 400 U HBIG was intramuscularly injected to 38 women of group B at 28
32
36 gestational weeks. 200 U HBIG was intramusculaly rinjected to 45 women of group C at 28
32
36 gestational weeks. There was no intervention in 22 women of control group. HBIG and HBVac were used to all the 132 newborns. Serum HBV-M and HBV-DNA of those infants were tested at 7 month of birth. Result: Intrauterine transmission rate of group A
B
C and control group was 7.4%
7.9%
11.1%
36.4%
separately. A significant difference was found between group A and control group
group B and control group
group C and control group(P<0.05). No significant difference was found among the interventional groups. Conclusion: It is effective and safe to use HBIG during pregnant. We can concluded that the method with 200 U injection 3 times can achieve the same effect with the other two methods (400 U 3 times
200 U 6 times). Obviously
it can be the cheapest project.
0
浏览量
2
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621